Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2022 Results Conference Call August 9, 2022 4:30 PM ET
Company Participants
Clint Tomlinson - IR
Dr. Christopher Missling - President and CEO
Sandra Boenisch - Principal Financial Officer
Conference Call Participants
Soumit Roy - Jones Research
Yun Zhong - BTIG
Raghuram Selvaraju - H.C. Wainwright
Clint Tomlinson
Good afternoon. Welcome to the Anavex Life Sciences’ Fiscal 2022 Third Quarter Conference Call. My name is Clint Tomlinson, and I’ll be your host for today’s call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. The call will also be available for replay on Anavex’s website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin, please note that during this conference call, the Company will make some projections and forward-looking statements. These statements will -- are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the Company’s filings with the SEC.
This includes, without limitation, the Company’s Forms 10-K and 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty and results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights.
And with that, I’d like to turn the call over to Dr. Missling.
Dr. Christopher Missling
Thank you, Clint. We appreciate everyone joining us on today’s conference call to review our most recently reported financial results and to provide a business update.
We are pleased with the continued advancement regarding our lead product candidate, ANAVEX 2-73 in Alzheimer’s disease and Rett syndrome. As we maintain our attention on the execution across each of our clinical programs and overall business operations.
We achieved a very important milestone at the end of June. With the last patient, last visit in the randomized placebo-controlled Phase 2b/3 study of ANAVEX 2-73 for the treatment of early Alzheimer disease. We are now focused on completion of associated end of trial activities in order to provide top line results of the placebo-controlled Phase 2b/3 study of ANAVEX 2-73 for the treatment of early Alzheimer’s disease. We are now focused on completion of associated end-of-trial activities in order to provide top-line results of the placebo-controlled Phase 2b/3 study of ANAVEX 2-73 in early Alzheimer’s disease, which are expected this coming fall. This is an indication, which is a condition of significant unmet need and economic burden. For which there are only limited approved pharmacological treatment options.